Compare Digital Realty Trust, Inc. (DLR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Novartis AG — how do they compare? Digital Realty Trust, Inc. trades at $178.53 (market cap $65.32B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 4.1× Digital Realty Trust, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 93 Days and Novartis AG for 82 Days on average.
| DLR | NVS | |
|---|---|---|
Market Cap | $65.32B | $268.57B |
Volume | 2,563,950 | 1,532,573 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $168.62 |
52-Week Low | $147.93 | $121.80 |
Typical Hold Time | 93 Days | 82 Days |
Enterprise Value | $84.03B | $309.89B |
Dividend Yield | 2.77% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $178.76, down 0.95% on the day, amid a bearish technical signal but strong fundamental momentum. The data center REIT shows robust revenue growth to $6.11B in 2025 with net income reaching $1.31B, though valuation metrics remain elevated with a P/E of 85.89. Recent news highlights AI infrastructure expansion through partnerships and record interconnection demand, supporting analyst optimism.
DLR presents a compelling long-term opportunity in the AI-driven data center space, with 69% analyst buy ratings and a $222.35 price target suggesting 24% upside. Key risks include high valuation multiples, significant capital expenditures, and sensitivity to interest rates. The company's strategic positioning in AI infrastructure and strong leasing activity provide fundamental support for growth.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
